Although diabetes and worsening glycemic control were not found to be associated with PCSK9 inhibitors in clinical trials (Carvalho et al., 2017; Chiu et al., 2020), it has been suggested that the FOURIER trial may not be robust enough to detect diabetes risk (van Bruggen and Luijendijk, 2019). The gene discussed is PCSK9; the disease is diabetes mellitus.